What’s the current market cap for Revvity stock?

Revvity (RVTY) has a market cap of $11B as of May 22, 2026.

What is the P/E ratio for Revvity stock?

The price to earnings (P/E) ratio for Revvity (RVTY) stock is 45.55 as of May 22, 2026.

Does Revvity stock pay dividends?

Yes, the Revvity (RVTY) stock pays dividends to shareholders. As of May 22, 2026, the dividend rate is $0.28 and the yield is 0.29%. Revvity has a payout ratio of 13.44% on a trailing twelve-month basis.

When is the next Revvity dividend payment date?

The next Revvity (RVTY) dividend payment is scheduled for August 07, 2026.

What is the beta indicator for Revvity?

Revvity (RVTY) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Revvity stock | $RVTY Share Price

13:30

15:10

16:45

18:25

20:00

About Revvity

Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.

Ticker

$RVTY

Sector

Health

Primary listing

NYSE

Employees

11,000

Headquarters

Waltham, United States

Website

www.revvity.com

Revvity Metrics

BasicAdvanced

$11bn

45.55

$2.09

1.05

$0.28

0.29%

What the Analysts think about Revvity

Analyst ratings (Buy, Hold, Sell) for Revvity stock.

Bulls say / Bears say

Revvity posted adjusted Q1 EPS of $1.06, beating consensus of $1.02. This highlights strong operational efficiency and cost management. (Reuters)

The diagnostics division showed strong growth, with revenue increasing 8% year-over-year to $349 million, supported by high demand for genetic screening products. (Reuters)

The life sciences tools unit reported Q1 revenue of $362 million, just above analyst expectations of $361.2 million, reflecting steady demand for reagents and instruments. (Reuters)

Management lowered the 2026 adjusted EPS forecast by about $0.15 to $5.20–$5.30, reflecting an earnings impact from the planned sale of the China immunodiagnostics business. (Reuters)

The full-year 2026 revenue projection was reduced to $2.81 billion–$2.84 billion from $2.96 billion–$2.99 billion, signaling a 4.5% drop in sales tied to the China market exit. (Reuters)

The planned sale of the China immunodiagnostics division, which represents roughly 6% of projected 2025 revenue, brings execution and timing risks until its anticipated completion in 2027. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 21 May 2026.

Revvity Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Revvity Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RVTY

Capital at risk

Market open

Upcoming events